Limited time75% off all plans
Get the app

Chronic Leukemias

On this page

Chronic Leukemias Overview - The Slow Burn

  • Insidious onset, primarily affecting older adults.
  • Clonal proliferation of more mature-appearing hematopoietic cells.
  • Slower progression compared to acute leukemias; often indolent course.
  • Frequently discovered incidentally during routine blood work.
  • Common features: fatigue, weight loss, splenomegaly, cytopenias (later stages).
  • Peripheral blood often shows ↑ specific mature cells.
  • Bone marrow is typically hypercellular with lineage-specific proliferation.

⭐ Chronic leukemias are generally insidious in onset and affect older adults, characterized by proliferation of more mature hematopoietic cells.

Chronic Myeloid Leukemia (CML) - Philly's Fatal Fusion

  • Myeloproliferative neoplasm (MPN); clonal stem cell disorder.
  • 📌 CML = City of Philadelphia, 9:22 PM; t(9;22) (BCR-ABL1 fusion gene).
  • Pathophysiology: Constitutively active tyrosine kinase → uncontrolled cell proliferation.
  • Key Features:
    • Insidious: fatigue, weight loss, splenomegaly.
    • Blood: ↑WBC (marked left shift), basophilia, eosinophilia, often thrombocytosis. Low LAP score.
  • Phases:
-   Chronic: <**10%** blasts.
-   Accelerated: **10-19%** blasts, ↑basophils >**20%**, worsening splenomegaly.
-   Blast Crisis: ≥**20%** blasts (myeloid/lymphoid).

*

  • Diagnosis: Bone marrow: hypercellular. Cytogenetics/FISH/PCR for BCR-ABL1.

⭐ The Philadelphia chromosome t(9;22)(q34;q11.2) resulting in the BCR-ABL1 fusion gene is the pathognomonic hallmark of CML.

  • Treatment: Tyrosine Kinase Inhibitors (TKIs) like Imatinib.

Chronic Lymphocytic Leukemia (CLL/SLL) - The Lymphocyte Flood

  • Most common adult leukemia (West); indolent B-cell neoplasm. SLL: tissue form.

  • Patho: Accumulation of clonal, mature but immunoincompetent B-cells.

  • Diagnosis: Absolute lymphocytosis >5000/μL (peripheral blood).

    • Smear: Small, mature lymphocytes; smudge cells (Gumprecht shadows).
  • Immunophenotype: CD19+, CD20+(dim), CD5+, CD23+. Surface Ig (dim).

  • Clinical: Often asymptomatic. Fatigue, lymphadenopathy, hepatosplenomegaly. B-symptoms less common.

  • Complications:

    • Infections (hypogammaglobulinemia).
    • Autoimmune cytopenias (AIHA, ITP).
    • Richter's Transformation (to DLBCL, ~2-10%).
  • Staging (Rai Simplified):

⭐ Characteristic immunophenotype for CLL is CD19+, CD20+ (dim), CD5+, and CD23+; smudge cells (crushed lymphocytes) are frequently seen on peripheral blood smears.

Hairy Cell Leukemia (HCL) - Trap 'Em Hairs

  • Rare, indolent B-cell neoplasm; M:F 4:1.
  • Pathogenesis: BRAF V600E mutation (>90%).
  • Clinical:
    • Pancytopenia.
    • Massive splenomegaly.
    • No lymphadenopathy (usually).
    • ↑ Susceptibility to atypical mycobacterial infections.
  • Morphology:
    • Peripheral blood: "Hairy cells" (lymphocytes with fine, circumferential cytoplasmic projections). Monocytopenia is characteristic.
    • Bone marrow: "Fried egg" appearance of cells; dry tap on aspiration due to marrow fibrosis (reticulin).
  • Key Test:
    • 📌 TRAP positive (Tartrate Resistant Acid Phosphatase).
  • Immunophenotype: Pan B-cell markers (CD19, CD20, CD22); specific: CD11c, CD25, CD103, Annexin A1. Hairy cell leukemia with TRAP stain

⭐ Hairy Cell Leukemia is characterized by pancytopenia, massive splenomegaly, 'hairy' B-lymphocytes in peripheral blood/bone marrow, and strong positivity for TRAP stain; BRAF V600E mutation is highly prevalent.

  • Rx: Cladribine (2-CdA), Pentostatin. Excellent prognosis with therapy.

High‑Yield Points - ⚡ Biggest Takeaways

  • CML: Philadelphia t(9;22), BCR-ABL1; TKIs; low LAP score.
  • CLL: Most common adult leukemia; CD5+/CD23+ B-cells, smudge cells; Richter's transformation.
  • Hairy Cell Leukemia: BRAF V600E; TRAP positive; "hairy" cells, pancytopenia; cladribine.
  • Polycythemia Vera: JAK2 V617F (>90%); ↑RBC mass, low EPO; aquagenic pruritus.
  • Essential Thrombocythemia: JAK2/CALR/MPL mutations; marked thrombocytosis; thrombotic/hemorrhagic risk.
  • Primary Myelofibrosis: JAK2/CALR/MPL mutations; marrow fibrosis, teardrop RBCs; massive splenomegaly.

Continue reading on Oncourse

Sign up for free to access the full lesson, plus unlimited questions, flashcards, AI-powered notes, and more.

CONTINUE READING — FREE

or get the app

Rezzy — Oncourse's AI Study Mate

Have doubts about this lesson?

Ask Rezzy, your AI Study Mate, to explain anything you didn't understand

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

START FOR FREE